Home › Research › Biomarkers
Plasma P-tau217, GFAP, and NfL as biomarkers for Alzheimer's disease: role in disease stratification, pathological progression, and cognitive decline
Feng-Feng Pan, Lin Huang, Ying Wang, Qi Huang, Yi-Hui Guan, Yue-hua Li, Fang Xie, Qi-Hao Guo. Alzheimer's & Dementia, 2025-12-10
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
In a Chinese cohort of 1,275 people spanning normal cognition to dementia, this study compared three blood markers: p-tau217 rose steadily as amyloid and tau pathology worsened and was very good at both ruling out early disease and flagging advanced tau pathology. GFAP (a marker of brain inflammation) appeared to interact with tau spread, while NfL (a marker of general nerve damage) was only weakly tied to Alzheimer's-specific pathology and seemed to reflect more generic brain injury and effects on planning/attention rather than memory.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 1,275 participants. In 1,275 people, blood p-tau217 rose as amyloid and tau pathology worsened and was very good at flagging advanced tau pathology, while GFAP appeared linked to amyloid-driven tau progression and NfL was only weakly tied to Alzheimer's-specific pathology. Reported effect size: p-tau217 AUC 0.959 for identifying advanced tau pathology.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Pan, F.-F., Huang, L., Wang, Y., Huang, Q., Guan, Y.-H., Li, Y.-h., et al. (2025). Plasma P-tau217, GFAP, and NfL as biomarkers for Alzheimer's disease: role in disease stratification, pathological progression, and cognitive decline. Alzheimer's & Dementia.
Vancouver
Pan F.-F, Huang L, Wang Y, Huang Q, Guan Y.-H, Li Y.-h, et al. Plasma P-tau217, GFAP, and NfL as biomarkers for Alzheimer's disease: role in disease stratification, pathological progression, and cognitive decline. Alzheimer's & Dementia. 2025.
BibTeX
@article{pan2025-c53cc9a6,
author = {Pan, Feng-Feng and Huang, Lin and Wang, Ying and Huang, Qi and Guan, Yi-Hui and Li, Yue-hua and Xie, Fang and Guo, Qi-Hao},
title = {{Plasma P-tau217, GFAP, and NfL as biomarkers for Alzheimer's disease: role in disease stratification, pathological progression, and cognitive decline}},
journal = {Alzheimer's \& Dementia},
year = {2025}
}
Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- 1,275 participants; amyloid PET, tau PET (n=584), and blood biomarkers all measured
- p-tau217 AUC of 0.959 for identifying advanced tau pathology
- Elevated GFAP was linked to amyloid-driven tau progression, suggesting a role for brain inflammation
- NfL correlated weakly with core Alzheimer's pathology; more tied to executive function decline than memory loss
Why it matters
In 1,275 people, blood p-tau217 rose as amyloid and tau pathology worsened and was very good at flagging advanced tau pathology, while GFAP appeared linked to amyloid-driven tau progression and NfL was only weakly tied to Alzheimer's-specific pathology. These are biomarker associations in a cohort, not evidence that measuring or changing them treats or prevents the disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcohort
- Participants1,275
- Effect sizep-tau217 AUC 0.959 for identifying advanced tau pathology
- Evidence strengthModerate
Limitations
Single-country (Chinese) cohort; NfL findings were only weakly specific to Alzheimer's pathology and may not generalize as a stand-alone diagnostic marker.
How this study scored 68/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded and indexed in PubMed because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 42 of the 62 points we could judge it on, which is 68 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & Dementia) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,275 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 0 / 2 | No PubMed ID and no DOI — scores zero (not stated in the record — scored 0) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 42 / 62 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 42 of the 62 points we could judge it on is 68 out of 100. |
| Total | 68 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.